Illumina, Inc. (ILMN) Jefferies Global Healthcare Conference 2026 November 17, 2026 5:30 AM EST.

Ankur Dhingra - Chief Financial Officer.

Tycho Peterson - Jefferies LLC, Research Division.

Tycho PetersonJefferies LLC, Research Division.

Okay. We're going to kick it off. I'm Tycho Peterson from the Life Science team. It's my pleasure to have Illumina. Welcome, Ankur.

Ankur DhingraChief Financial Officer.

Tycho PetersonJefferies LLC, Research Division.

Maybe just set the stage here, just some of the -- coming out of the third quarter, some of the gives and takes and how you're thinking about trends heading into next year.

Ankur DhingraChief Financial Officer.

Industry observers note that yes, sure. So as a reminder, we're very pleased with how Q3 went overall panned out for us. As a reminder for everyone, we laid out a framework for Illumina a couple of years ago in 2024 in terms of returning the company towards high single-digit growth. And we've made tremendous progress towards that despite different changes that happened in the end markets for us. And 2026 is a step there where we are steadily in the mid-single-digit growth over the quarters as well as in our guide for Q4. And Q3 was the right step in that business as well.

Some highlights. Again, our placements on the instrumentation remain very strong. We've noted our clinical business is where a lot of this upside demand has been coming from, especially in the U.S. as well as a little bit outside the U.S. as well on the clinical markets. The consumables growth has held steady in line with both the increasing installed base as well as where it can go going forward.

And then we've made a lot of progress in building up our multiomics.

→ Read original article